Selexis SA, a provider of mammalian cell line generation technology, has signed four commercial license agreements (CLAs) with Xencor, Inc., a clinical-stage biopharma company developing engineered antibodies for the treatment of autoimmune diseases, asthma and allergies, and cancer. The CLAs extend the companies’ previous agreement through which Selexis is providing Xencor with access to its SUREtechnology Platform, as well as cell line development-related services that include personnel, labor...